logo
Mote scientists, partners unveil arsenal of tools aimed at fighting red tide

Mote scientists, partners unveil arsenal of tools aimed at fighting red tide

Yahoo30-01-2025

SARASOTA, Fla. (WFLA) – Mote Marine Laboratory received millions of dollars from the state for a red tide mitigation initiative a few years back. Now, alongside their partners, scientists unveiled some of the tools they've developed to tackle the harmful algal blooms.
'The state of Florida is leading in the U.S. and indeed leading in the world in developing new technologies to fight, not only red tide but other harmful algal blooms in freshwater and marine ecosystems all around the United States and all around the world,' said Mote CEO Dr. Michael Crosby.
QVC US and HSN operations close campus in St. Petersburg
Scientists looked at more than 300 different approaches and narrowed it down to about two dozen. Three of those have already received state and federal approvals to be deployed.
'Our mantra is with all of these technologies.. none of them will do any greater harm to the environment than the red tide is already doing,' said Dr. Crosby.
Mote broke down three initiatives ready for deployment in a news release this week.
Principal Investigator: Dr. Dana WetzelCLEAR is a novel, naturally derived biocide developed by Mote's Environmental Laboratory for Forensics. Harnessing the properties of natural plant-based compounds, CLEAR targets K. brevis with no environmental impact. CLEAR's active ingredients are classified as Generally Recognized as Safe (GRAS) by the FDA, and studies show no measurable accumulation in the environment. The all-natural biocide degrades fully within half a day, ensuring its safety for marine ecosystems. Regulatory approvals from the EPA, FDACS, and DEP allow for rapid deployment of CLEAR in the event of a bloom.
Mote has developed multiple formulations of CLEAR to ensure versatility. Engineered particle treatments can be deployed on surface waters via vessel-mounted blowers, drones, or backpack sprayers. For underwater applications, remotely operated vehicles (ROVs) or autonomous underwater vehicles (AUVs) deliver the liquid form directly into blooms. This liquid application may also be deployed sub-surface with a specially equipped boat. CLEAR-embedded dissolvable beads provide sustained protection for 30-60 days, ideal for canals, marinas, and other vulnerable areas. This multi-faceted approach ensures targeted and effective mitigation.
Principal Investigator: Dr. Rich PierceXtreme is a natural, non-toxic water treatment product developed by Heartland Energy Group. Previously used for blue-green algae (a freshwater HAB), Xtreme has demonstrated significant effectiveness against K. brevis. Lab testing and mesocosm experiments at Mote confirmed Xtreme's ability to reduce red tide cells and brevetoxins while posing no harm to marine life, including commercially important clams. Xtreme offers a natural solution that could help control blooms. This product is deployed by a large handheld sprayer.
Principal Investigator: Dr. Rich PierceOZONIX® is a patented, chemical-free water treatment technology that combines several processes to eliminate K. brevis cells and their toxins. It uses hydrodynamic cavitation (a process that creates bubbles in the water to break apart harmful substances), ozone injection (adding ozone gas to the water, which helps break down toxins), ultrasonic acoustic cavitation (using sound waves to create bubbles that break down harmful materials), and electrochemical oxidation (a process where electricity helps remove contaminants). These techniques work by running large hoses into the water that are connected to a trailer outfitted with a complex water system. Together, these techniques effectively address the red tide algae and its toxins.
When and where to deploy these technologies will be up to state and federal leaders.
'This is huge for the state of Florida, it is huge for the United States, it is huge for the world to be able to fight these very toxic negative impacts to our environment, to our economy and to our quality of life,' said Dr. Crosby. 'We are working very patiently, but very deliberately through the permitting process for the other dozen and a half technologies. We need them all to be approved, but we do have to work through those processes. We are ready to deploy now. What we need to do is a scale this up so that we can have large-scale deployment of all of these technologies,' he continued.
Partners of Mote include Senior Global Product Manager, Heartland Energy Group, Prescott Clean Water, AquaTech Eco Consultants, Hull's Environmental Services, and A-C-T Environmental & Infrastructure.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial
Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial

Yahoo

time2 days ago

  • Yahoo

Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial

SOUTH SAN FRANCISCO, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced it will release topline data from the norovirus Phase I trial before the market open on Wednesday, June 11, 2025. The Vaxart senior management team will host a live conference call on the same date beginning at 8:30 a.m. Eastern Time to review the data and provide a trial update. The conference call can be accessed using the following information: Webcast: Click hereDate: Wednesday, June 11, 2025 – 8:30 a.m. ETDomestic: (877) 407-0832International: (201) 689-8433Conference ID: 13754315 Investors may submit written questions in advance of the conference call to ir@ A replay of the webcast will be available on the Company's website at following the conclusion of the event. About VaxartVaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart's development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart's first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists. Contact Vaxart Media and Investor Relations: Matt Steinberg FINN Partners IR@ (646) 871-8481 This press release was published by a CLEAR® Verified in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial
Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial

Yahoo

time2 days ago

  • Yahoo

Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial

SOUTH SAN FRANCISCO, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced it will release topline data from the norovirus Phase I trial before the market open on Wednesday, June 11, 2025. The Vaxart senior management team will host a live conference call on the same date beginning at 8:30 a.m. Eastern Time to review the data and provide a trial update. The conference call can be accessed using the following information: Webcast: Click hereDate: Wednesday, June 11, 2025 – 8:30 a.m. ETDomestic: (877) 407-0832International: (201) 689-8433Conference ID: 13754315 Investors may submit written questions in advance of the conference call to ir@ A replay of the webcast will be available on the Company's website at following the conclusion of the event. About VaxartVaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart's development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart's first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists. Contact Vaxart Media and Investor Relations: Matt Steinberg FINN Partners IR@ (646) 871-8481 This press release was published by a CLEAR® Verified individual.

May sets astonishing heat record in Tampa
May sets astonishing heat record in Tampa

Yahoo

time04-06-2025

  • Yahoo

May sets astonishing heat record in Tampa

Jeff Berardelli is WFLA's Chief Meteorologist and Climate Specialist TAMPA, Fla. (WFLA)—It was the second warmest May on record in Tampa. Impressive, but not astonishing. What is astonishing is that Tampa broke its record for the all-time warmest May morning – not just once, but four times! Technically, it is known as the 'record warm minimum'. Records have been kept in Tampa since 1890, and the warmest morning low in those 130+ years has been 79 degrees. But in May 2025, Tampa stayed at or above the 80-degree mark on four mornings. On May 29th, the temperature never fell below 81. The meteorological reason for this is that the Gulf has been abnormally warm this May, in part due to a relatively dry, sunny May under high pressure and light winds. The end of May featured eastern Gulf temperatures 5 to 7 degrees F above normal. Also, the Bay Area has had onshore flow from the Gulf in late May. This aided in pushing Tampa's wake-up temperatures to unseen heights. But warmer mornings are not a new phenomenon. Morning lows have been trending up for decades. It's even more remarkable when you dig deeper into the numbers for May. 29 out of the 31 record warm minimum temperatures have occurred since the year 2000 – that's 94%. Remember, records have been kept since 1890. The obvious culprit for this is human-caused climate change. This encompasses both urbanization and the greenhouse effect due to carbon pollution from the burning of fossil fuels. Overall, since 1970, Tampa has warmed 4.3 degrees Fahrenheit. That's a lot! While both daytime and morning temperatures are rising, it is the morning lows that are rising faster. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store